Overexpression of activated leukocute cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation

Ye,Min; Du,Yan‑Lei; Nie,Yu‑Qiang; Zhou,Zhi‑Wei; Cao,Jie; Li,Ying‑Fei

doi:10.3892/mmr.2014.2933

Overexpression of activated leukocute cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation

Authors:
- Min Ye
- Yan‑Lei Du
- Yu‑Qiang Nie
- Zhi‑Wei Zhou
- Jie Cao
- Ying‑Fei Li
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Guangzhou Key Laboratory of Digestive Disease, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of Gastroenterology, Luohu District People's Hospital, Shenzhen, Guangdong 518000, P.R. China, Department of General Surgery, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
Published online on: November 12, 2014 https://doi.org/10.3892/mmr.2014.2933
Pages: 2004-2012

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activated leukocyte cell adhesion molecule (ALCAM) has been identified as a novel potential molecular marker of human tumors. The present study aimed to assess ALCAM as a prognostic marker for gastric cancer (GC), and to explore the mRNA deregulation underlying the abnormal expression of ALCAM. The mRNA and protein expression of ALCAM in GC and adjacent non‑tumor tissues from 66 patients with GC were analyzed. The association between miR‑9 and ALCAM mRNA expression was determined by quantitative polymerase chain reaction. Serum soluble ALCAM (sALCAM) was analyzed by ELISA in 72 patients with GC, 82 patients with gastric precancerous lesions and 73 controls. ALCAM and sALCAM levels were associated with certain clinicopathological variables, including overall survival. Compared with the non‑tumor tissues, the expression of ALCAM mRNA in the GC tissues was significantly upregulated (P=0.013). The expression of miR‑9 was reduced and inversely correlated with ALCAM mRNA levels in GC tissues and cell lines. The ALCAM mRNA level was reduced following ectopic overexpression of miR‑9 in SGC‑7901 human gastric cancer cells. The rates of membranous and cytoplasmic expression of ALCAM in GC tissues were 59.1 and 48.48%, respectively, and the serum sALCAM levels were significantly elevated in patients with GC. Elevated ALCAM mRNA, membranous ALCAM expression in GC tissues and high sALCAM levels are associated with advanced tumor stage, lymphatic invasion and shorter overall survival duration. The results of the current study indicated that membranous ALCAM expression and high serum sALCAM levels are independent prognostic markers of poor survival for patients with GC, and that the overexpression of ALCAM may be due to the downregulation of miR‑9.

View Figures

View References

1	Ofori-Acquah SF and King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 151:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
2	Bowen MA, Patel DD, Li X, et al: Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 181:2213–2220. 1995. View Article : Google Scholar : PubMed/NCBI
3	Patel DD, Wee SF, Whichard LP, et al: Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med. 181:1563–1568. 1995. View Article : Google Scholar : PubMed/NCBI
4	Bruder SP, Ricalton NS, Boynton RE, et al: Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res. 13:655–663. 1998. View Article : Google Scholar : PubMed/NCBI
5	Sekine-Aizawa Y, Omori A and Fujita SC: MuSC, a novel member of the immunoglobulin superfamily, is expressed in neurons of a subset of cranial sensory ganglia in the mouse embryo. Eur J Neurosci. 10:2810–2824. 1998. View Article : Google Scholar : PubMed/NCBI
6	Cortés F, Deschaseaux F, Uchida N, et al: HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues. Blood. 93:826–837. 1999.PubMed/NCBI
7	Fujiwara H, Tatsumi K, Kosaka K, et al: Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88:3437–3443. 2003. View Article : Google Scholar : PubMed/NCBI
8	Weidle UH, Eggle D, Klostermann S and Swart GW: ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics. 7:231–243. 2010.PubMed/NCBI
9	Kristiansen G, Pilarsky C, Wissmann C, et al: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate. 54:34–43. 2003. View Article : Google Scholar
10	Weichert W, Knösel T, Bellach J, Dietel M and Kristiansen G: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 57:1160–1164. 2004. View Article : Google Scholar : PubMed/NCBI
11	Hein S, Müller V, Köhler N, et al: Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue. Breast Cancer Res Treat. 129:347–360. 2011. View Article : Google Scholar
12	Kijima N, Hosen N, Kagawa N, et al: CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol. 14:1254–1264. 2012. View Article : Google Scholar :
13	Ishiguro F, Murakami H, Mizuno T, et al: Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer. J Surg Res. 179:24–32. 2013. View Article : Google Scholar
14	Lunter PC, van Kilsdonk JW, van Beek H, et al: Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res. 65:8801–8808. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ikeda K and Quertermous T: Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem. 279:55315–55323. 2004. View Article : Google Scholar : PubMed/NCBI
16	Tachezy M, Zander H, Marx AH, et al: ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One. 7:e390182012. View Article : Google Scholar : PubMed/NCBI
17	Tachezy M, Effenberger K, Zander H, et al: ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer. 131:396–405. 2012. View Article : Google Scholar
18	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
19	Sethupathy P, Megraw M and Hatzigeorgiou AG: A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods. 3:881–886. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mendes ND, Freitas AT and Sagot MF: Current tools for the identification of miRNA genes and their targets. Nucleic Acids Res. 37:2419–2433. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Gu Z, Ni P, et al: NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res. 39:6440–6455. 2011. View Article : Google Scholar : PubMed/NCBI
22	Liu N, Sun Q, Chen J, et al: MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-κB1 pathway. Oncol Rep. 28:961–968. 2012.PubMed/NCBI
23	Selcuklu SD, Donoghue MT, Rehmet K, et al: MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem. 287:29516–29528. 2012. View Article : Google Scholar : PubMed/NCBI
24	de Martel C, Forman D and Plummer M: Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 42:219–240. 2013. View Article : Google Scholar : PubMed/NCBI
25	Ishigami S, Ueno S, Arigami T, et al: Clinical implication of CD166 expression in gastric cancer. J Surg Oncol. 103:57–61. 2011. View Article : Google Scholar
26	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
27	Lauwers GY, Carneiro F and Graham DY: Gastric carcinoma. WHO Classification of tumors of the digestive system. Bosman FT, Carneiro F and Hruban RH: IARC Press; Lyon: pp. 48–58. 2010
28	van den Oord CJJ, van Muijen GN, Weidle UH, Bloemers HP and Swart GW: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 156:769–774. 2000. View Article : Google Scholar : PubMed/NCBI
29	Ishiguro F, Murakami H, Mizuno T, et al: Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma. J Thorac Oncol. 7:890–899. 2012. View Article : Google Scholar : PubMed/NCBI
30	van Kempen LC, Nelissen JM, Degen WG, et al: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem. 276:25783–25790. 2001. View Article : Google Scholar : PubMed/NCBI
31	Nelissen JM, Peters IM, de Grooth BG, van Kooyk Y and Figdor CG: Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. Mol Biol Cell. 11:2057–2068. 2000. View Article : Google Scholar : PubMed/NCBI
32	Jannie KM, Stipp CS and Weiner JA: ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells. PLoS One. 7:e393302012. View Article : Google Scholar : PubMed/NCBI
33	Tomita K, van Bokhoven A, Jansen CF, Bussemakers MJ and Schalken JA: Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. Biochem Biophys Res Commun. 267:870–874. 2000. View Article : Google Scholar : PubMed/NCBI
34	Mezzanzanica D, Fabbi M, Bagnoli M, et al: Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res. 14:1726–1733. 2008. View Article : Google Scholar : PubMed/NCBI
35	Rosso O, Piazza T, Bongarzone I, et al: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res. 5:1246–1253. 2007. View Article : Google Scholar
36	Weidle UH, Eggle D and Klostermann S: L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res. 29:4919–4931. 2009.
37	Kahlert C, Weber H, Mogler C, et al: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101:457–464. 2009. View Article : Google Scholar : PubMed/NCBI
38	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI